| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10016573 | HBV | ENSG00000102468.11 | protein_coding | HTR2A | No | No | 3356 | P28223 |
| TVIS44041305 | HTLV-1 | ENSG00000102468.11 | protein_coding | HTR2A | No | No | 3356 | P28223 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | HTR2A |
|---|---|
| DrugBank ID | DB16351 |
| Drug Name | Volinanserin |
| Target ID | BE0000451 |
| UniProt ID | P28223 |
| Regulation Type | antagonist |
| PubMed IDs | 9272484; 24216279 |
| Citations | Grunder G, Yokoi F, Offord SJ, Ravert HT, Dannals RF, Salzmann JK, Szymanski S, Wilson PD, Howard DR, Wong DF: Time course of 5-HT2A receptor occupancy in the human brain after a single oral dose of the putative antipsychotic drug MDL 100,907 measured by positron emission tomography. Neuropsychopharmacology. 1997 Sep;17(3):175-85. doi: 10.1016/S0893-133X(97)00044-4.@@Nemeth K, Palko R, Kovacs P, Visy J: Development of novel chiral capillary electrophoresis methods for the serotonin receptor (5-HT2A) antagonist MDL 100,907 (volinanserin) and for its key intermediate compound. J Pharm Biomed Anal. 2014 Jan;88:579-83. doi: 10.1016/j.jpba.2013.10.017. Epub 2013 Oct 23. |
| Groups | Investigational |
| Direct Classification | |
| SMILES | COC1=C(OC)C(=CC=C1)[C@H](O)C1CCN(CCC2=CC=C(F)C=C2)CC1 |
| Pathways | |
| PharmGKB | |
| ChEMBL | CHEMBL74355 |
